Reinstatement to Official Quotation
Open PDF
| Stock | Cynata Therapeutics Ltd (CYP.ASX) |
|---|---|
| Release Time | 19 Jun 2026, 9:22 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Cynata Therapeutics Reinstated on ASX
Key Points
- Trading suspension lifted after trial results announcement
- Phase 3 Osteoarthritis Trial results pending
- Phase 2 Graft versus Host Disease Trial results pending
- Immediate impact on stock price expected
Full Summary
Cynata Therapeutics Limited (ASX: CYP) announced the reinstatement of its securities on the Australian Securities Exchange (ASX) following the suspension. The suspension will be lifted immediately after the company releases announcements regarding the results of the Phase 3 Osteoarthritis Trial and Phase 2 Graft versus Host Disease Trial. This reinstatement follows the completion of the necessary announcements, which are expected to have a significant impact on the company's stock price.
Outlook
Pending the release of the Phase 3 and Phase 2 trial results, Cynata Therapeutics expects to see a significant impact on its stock price.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In